Literature DB >> 15094378

ANGPTL3 is increased in both insulin-deficient and -resistant diabetic states.

Kouichi Inukai1, Youhei Nakashima, Masaki Watanabe, Susumu Kurihara, Takuya Awata, Hideki Katagiri, Yoshitomo Oka, Shigehiro Katayama.   

Abstract

Angiopoietin-like protein 3 (ANGPTL3) is secreted by the liver and was recently postulated to be an important hormone regulating serum triglyceride levels. In the present study, in order to clarify the regulation of ANGPTL3 gene expression in diabetic states, we examined mRNA and protein levels of ANGPTL3 in the livers of diabetic animals. The level of ANGPTL3 mRNA was increased approximately 2.2-fold in the livers of streptozotocin (STZ) diabetic mice, and this effect was reversed by administration of insulin. Furthermore, the level of ANGPTL3 mRNA was increased more than 3.0-fold in type 2 diabetic obese mice, db/db mice, as compared with age matched lean littermates. The hepatic level of ANGPTL3 protein was also increased in these diabetic mice to an extent similar to that of ANGPTL3 mRNA. Thus, the expression of ANGPTL3 was enhanced in both insulin-deficient and -resistant diabetic states. These results strongly suggest ANGPTL3 to play an important role in hyperlipidemia in diabetes.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15094378     DOI: 10.1016/j.bbrc.2004.03.151

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  20 in total

1.  Inhibition of cardiac lipoprotein utilization by transgenic overexpression of Angptl4 in the heart.

Authors:  Xinxin Yu; Shawn C Burgess; Hongfei Ge; Kenny K Wong; R Haris Nassem; Daniel J Garry; A Dean Sherry; Craig R Malloy; Joel P Berger; Cai Li
Journal:  Proc Natl Acad Sci U S A       Date:  2005-01-19       Impact factor: 11.205

2.  Angiopoietin-like proteins as therapeutic targets for cardiovascular disease: focus on lipid disorders.

Authors:  Marco Bruno Morelli; Christopher Chavez; Gaetano Santulli
Journal:  Expert Opin Ther Targets       Date:  2020-01-15       Impact factor: 6.902

3.  Role of angiopoietin-like protein 3 in sugar-induced dyslipidemia in rhesus macaques: suppression by fish oil or RNAi.

Authors:  Andrew A Butler; James L Graham; Kimber L Stanhope; So Wong; Sarah King; Andrew A Bremer; Ronald M Krauss; James Hamilton; Peter J Havel
Journal:  J Lipid Res       Date:  2020-01-09       Impact factor: 5.922

Review 4.  ANGPTL3 and Apolipoprotein C-III as Novel Lipid-Lowering Targets.

Authors:  Ioannis Akoumianakis; Evangelia Zvintzou; Kyriakos Kypreos; Theodosios D Filippatos
Journal:  Curr Atheroscler Rep       Date:  2021-03-10       Impact factor: 5.113

5.  Genetics of non-conventional lipoprotein fractions.

Authors:  Alexis C Frazier-Wood
Journal:  Curr Genet Med Rep       Date:  2015-08-29

6.  Betatrophin provides a new insight into diabetes treatment and lipid metabolism (Review).

Authors:  Jin-Zhou Zhu; Chao-Hui Yu; You-Ming Li
Journal:  Biomed Rep       Date:  2014-05-20

Review 7.  Angiopoietin-like 3 in lipoprotein metabolism.

Authors:  Sander Kersten
Journal:  Nat Rev Endocrinol       Date:  2017-10-06       Impact factor: 43.330

8.  Effects of angiopoietin-like protein 3 deficiency on postprandial lipid and lipoprotein metabolism.

Authors:  Ilenia Minicocci; Anna Tikka; Eleonora Poggiogalle; Jari Metso; Anna Montali; Fabrizio Ceci; Giancarlo Labbadia; Mario Fontana; Alessia Di Costanzo; Marianna Maranghi; Aldo Rosano; Christian Ehnholm; Lorenzo Maria Donini; Matti Jauhiainen; Marcello Arca
Journal:  J Lipid Res       Date:  2016-04-03       Impact factor: 5.922

9.  A Possible Mechanism: Vildagliptin Prevents Aortic Dysfunction through Paraoxonase and Angiopoietin-Like 3.

Authors:  Qian Zhang; Xinhua Xiao; Jia Zheng; Ming Li; Miao Yu; Fan Ping; Tong Wang; Xiaojing Wang
Journal:  Biomed Res Int       Date:  2018-05-23       Impact factor: 3.411

10.  Silencing of ANGPTL 3 (angiopoietin-like protein 3) in human hepatocytes results in decreased expression of gluconeogenic genes and reduced triacylglycerol-rich VLDL secretion upon insulin stimulation.

Authors:  Anna Tikka; Jarkko Soronen; Pirkka-Pekka Laurila; Jari Metso; Christian Ehnholm; Matti Jauhiainen
Journal:  Biosci Rep       Date:  2014-12-12       Impact factor: 3.840

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.